173.25 +0.06 (0.03%)
After hours: 4:32PM EDT
|Bid||173.26 x 900|
|Ask||200.00 x 800|
|Day's Range||168.63 - 173.40|
|52 Week Range||105.05 - 173.40|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||176.88|
President, CEO and Chairman of Dexcom Inc (30-Year Financial, Insider Trades) Kevin R Sayer (insider trades) sold 10,000 shares of DXCM on 08/15/2019 at an average price of $156.12 a share. Continue reading...
Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Dow futures: Wednesday's stock market action wasn't positive, but it teaches key lessons. Don't fight the Fed, focus on the real leaders and don't buy before earnings.
The medical device maker delivered strong revenue and adjusted earnings growth in Q2 thanks to continued popularity of its G6 continuous glucose monitoring system.
Dexcom earnings of 8 cents per share, minus certain items, on $336.4 million in second-quarter sales beat estimates Wednesday. The company also raised its guidance. But Dexcom stock slipped.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott Laboratories plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters. Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday.
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
President, CEO and Chairman of Dexcom Inc (NASDAQ:DXCM) Kevin R Sayer sold 6,000 shares of DXCM on 07/08/2019 at an average price of $146.25 a share.